Cellebrite (CLBT) Q1 2026 earnings summary

Executive summary

• Q1 2026 delivered ARR of $493M, up 21% year-over-year, and revenue of $128.3M, up 19%, with strong growth across all regions and customer segments.

• Adjusted EBITDA rose 29% to $30.6M, with a margin of 23.9%, and free cash flow margin for the trailing 12 months was 32%.

• Major AI-driven products, including Genesis and Guardian Investigate, launched with strong early adoption and positive customer feedback.

• Achieved FedRAMP High authorization, expanding U.S. federal opportunities.

• Closed acquisitions of SCG Canada and Corellium, enhancing drone forensics and mobile access capabilities.

Financial highlights

• Subscription revenue grew 23% year-over-year to $117.9M, now representing 86% of total revenue.

• Gross profit increased to $110.2M (non-GAAP, 85.9% margin); GAAP gross profit was $105.9M (82.5% margin).

• Adjusted EBITDA margin expanded to 23.9%, with net income at $30.6M or $0.12 per diluted share (non-GAAP).

• Free cash flow for the trailing twelve months was $158.6M (32% margin).

• Ended Q1 with $535M in cash equivalents and investments.

Outlook and guidance

• Q2 2026 ARR expected at $510M–$513M, with revenue of $130M–$133M and adjusted EBITDA of $29M–$31M (margin 22%–23%).

• Full-year 2026 ARR guidance of $567M–$573M (18–19% growth), revenue of $565M–$571M, and adjusted EBITDA margin of 26–27%.

• Guidance reflects confidence from expanded portfolio, pipeline, and recent acquisitions.